Overview
- Hims & Hers said it will stop offering access to a compounded semaglutide pill days after launching the $49 introductory product.
- The FDA announced plans to restrict GLP-1 ingredients used in non‑approved compounded drugs and warned against portraying such products as equivalent to FDA‑approved medicines.
- HHS General Counsel Mike Stuart referred Hims & Hers to the Department of Justice for potential violations of federal law.
- Novo Nordisk threatened legal and regulatory action, arguing mass‑compounded copies of its Wegovy pill are unlawful and pose patient safety risks.
- The shelved pill was not FDA‑approved or clinically tested, and Hims & Hers shares fell sharply in after‑hours trading following the enforcement signals.